Women are usually advised to interrupt breastfeeding during chemotherapy for concerns of serious side-effects to the infant. However, the passage of cytotoxic drugs in human milk has been poorly studied.
After a multidisciplinary discussion, the patient was advised to pump her breasts twice daily during CRT in order to maintain milk production. To decide when breastfeeding could be safely resumed, we evaluated the pharmacokinetics of 5-FU in milk.
The patient received standard CRT with 5-FU 200 mg/m 2 /day as i.v. continuous infusion concurrently with pelvic radiotherapy. Samples of peripheral blood were taken before the start of 5-FU and after 1, 2 and 5 weeks. Milk samples were obtained before, during and up to 10 days following the completion of therapy.
5-FU concentrations were measured using an highperformance liquid chromatography (HPLC) method [1] modified and optimized for plasma and milk samples. Four plasma samples were collected and analyzed. The concentration of 5-FU in plasma ranged between 11.14 and 114.95 lM ( Figure 1A and B). Thirty-three milk samples were collected and tested. 5-FU levels were undetectable in milk at any time during and after CRT treatment. To validate the HPLC methodology used, we carried out parallel analyses on human milk spiked with different concentrations of 5-FU, which were stored, extracted and measured in the same conditions. 5-FU was detected in the validation samples with a limit of detection at 0.5 lM (Figure1C and D) .
The patient completed the planned treatment and eventually underwent radical surgery without complications. Ten days after surgery, when pharmacokinetics results were available, the patient tried to resume breastfeeding, but her infant refused to latch.
Breastfeeding is an essential physiologic process that provides nutrition and protects the child against infection, immunologic disorders and some types of cancer during adulthood [2, 3] . Nevertheless and despite the lack of evidence, breastfeeding is usually not recommended during maternal chemotherapy because of the potential toxic effects to the infant.
In this case, we report for the first time that 5-FU was undetectable at any time during and following CRT, although maternal plasma concentrations reflected normal pharmacokinetics. The amount of a drug or its metabolites excreted into milk is dependent upon several factors: lipid solubility, molecular size, ionization, protein binding and halflife in maternal plasma [4] . 5-FU has a short half-life and a high protein bound in serum [5] ; these factors probably accounted for the undetectable levels of 5-FU in milk.
Our results are reassuring, but genetic background and plasma levels variability might influence 5-FU distribution into milk. Collecting breast milk for drug assays during and after chemotherapy, as impractical as this approach may seem, could provide valuable information to counsel patients receiving chemotherapy who are willing to resume breastfeeding after the end of treatment. 
